101 related articles for article (PubMed ID: 8598120)
1. Immunoluminometric assay for determining CA 72-4 in patients with gynecological tumors.
Heinze T; Greiner-Mai E
Clin Chem; 1996 Mar; 42(3):472-4. PubMed ID: 8598120
[No Abstract] [Full Text] [Related]
2. CA 19-9 and CA 125 determination by immunoluminometric assay.
Plebani M; Faggian D; Masiero M; Giacomini A; Burlina A
J Clin Chem Clin Biochem; 1990 Dec; 28(12):919-21. PubMed ID: 2081962
[TBL] [Abstract][Full Text] [Related]
3. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
4. Comparison of an immunoradiometric and an immunoluminometric assay for the evaluation of the tumour associated antigens CA 19-9 and CA 125.
Mader RM; Steger GG; Braun J; Rainer H
Eur J Clin Chem Clin Biochem; 1994 Feb; 32(2):85-90. PubMed ID: 8003582
[TBL] [Abstract][Full Text] [Related]
5. [Protocol for the correct evaluation of CA 125 in pelvic tumescence].
Bonelli P; Melpignano M; Piombo S; Franchini D; Condemi V
J Nucl Med Allied Sci; 1990; 34(4 Suppl):75-8. PubMed ID: 2092154
[No Abstract] [Full Text] [Related]
6. [Experiences with the cancer marker CA 125 in gynecologic diseases].
Pilgrim G; von Broen B; Johannsmeyer KD
Z Gesamte Inn Med; 1989 Apr; 44(8):251-4. PubMed ID: 2741520
[TBL] [Abstract][Full Text] [Related]
7. Combined detection of tumor markers and serum inflammatory factors in the diagnosis and treatment of gynecologic oncology.
Wang HP; Wu HY; Wang Y; Wang L
J Biol Regul Homeost Agents; 2017; 31(3):691-695. PubMed ID: 28956419
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer mucin antigen (BCM) determination by IMX: a preliminary study of epidemiological distribution of the serum levels in gynecological diseases.
Torre GC; Barbetti V; Lanfranco E; Robutti M; Foglia M; Corongiu F; Vigliercio GP
J Nucl Med Allied Sci; 1990; 34(4 Suppl):59-62. PubMed ID: 2092151
[No Abstract] [Full Text] [Related]
9. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass.
Schutter EM; Davelaar EM; van Kamp GJ; Verstraeten RA; Kenemans P; Verheijen RH
Am J Obstet Gynecol; 2002 Aug; 187(2):385-92. PubMed ID: 12193930
[TBL] [Abstract][Full Text] [Related]
10. Highly-sensitive troponin I is increased in patients with gynecological cancers.
Danese E; Montagnana M; Giudici S; Aloe R; Franchi M; Guidi GC; Lippi G
Clin Biochem; 2013 Aug; 46(12):1135-1138. PubMed ID: 23660299
[TBL] [Abstract][Full Text] [Related]
11. Luminoimmunometric assay of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA-125) in breast cancer patients.
el-Ahmady O; Halim AB; Eissa S
Dis Markers; 1993 Sep; 11(2-3):83-90. PubMed ID: 8261736
[TBL] [Abstract][Full Text] [Related]
12. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K].
Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C
Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444
[TBL] [Abstract][Full Text] [Related]
13. [Value of the tumor markers CA 125, Ca 19-9, CA 15-3 and CEA in endometriosis].
Cirkel U; Ochs H; Latussek B; Schneider HP
Geburtshilfe Frauenheilkd; 1991 Aug; 51(8):626-31. PubMed ID: 1936874
[TBL] [Abstract][Full Text] [Related]
14. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.
Zhang Z; Barnhill SD; Zhang H; Xu F; Yu Y; Jacobs I; Woolas RP; Berchuck A; Madyastha KR; Bast RC
Gynecol Oncol; 1999 Apr; 73(1):56-61. PubMed ID: 10094881
[TBL] [Abstract][Full Text] [Related]
15. [Value of neopterin as an oncologic laboratory parameter--observations in gynecologic tumors].
von Broen B; Kavungu P
Z Gesamte Inn Med; 1990 Apr; 45(8):223-5. PubMed ID: 2378135
[TBL] [Abstract][Full Text] [Related]
16. Serum placental alkaline phosphatase (PLAP) in gynecologic malignancies--with special reference to the combination of PLAP and CA54/61 assay.
Nozawa S; Udagawa Y; Ohkura H; Negishi Y; Akiya K; Inaba N; Takamizawa H; Kimura E; Terashima Y
Clin Chim Acta; 1990 Jan; 186(2):275-84. PubMed ID: 2178810
[TBL] [Abstract][Full Text] [Related]
17. A multicentre evaluation of the CA 15-3 assay, CA 19-9 assay and CA 125 II assay on the Bayer Immuno 1 System.
Römer M; Haeckel R; Brux B; Sinha P; Raiko I; Krieg M; Stark M; Seidel D; Hübner U; Schmitz G
Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):637-44. PubMed ID: 9298356
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value.
Bonfrer JM; Korse CM; Verstraeten RA; van Kamp GJ; Hart GA; Kenemans P
Clin Chem; 1997 Mar; 43(3):491-7. PubMed ID: 9068593
[TBL] [Abstract][Full Text] [Related]
19. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.
Bon GG; Kenemans P; Verstraeten R; van Kamp GJ; Hilgers J
Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):107-14. PubMed ID: 8571992
[TBL] [Abstract][Full Text] [Related]
20. [A fundamental and clinical investigation of cancer antigen 130 (CA 130) in the field of obstetrics and gynecology].
Inaba N; Okajima Y; Ota Y; Fukazawa I; Yamaguchi T; Sato N; Sudo H; Milanga M; Takamizawa H; Fujii S
Nihon Gan Chiryo Gakkai Shi; 1989 Oct; 24(10):2426-35. PubMed ID: 2614181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
